Last reviewed · How we verify

Gasmotin — Competitive Intelligence Brief

Gasmotin (MOSAPRIDE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mosapride. Area: Cardiovascular.

marketed mosapride Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Gasmotin (MOSAPRIDE). Mosapride works by enhancing acetylcholine release in the gastrointestinal tract, increasing motility.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Gasmotin TARGET MOSAPRIDE marketed mosapride Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9
Gasmotin Gasmotin Daewoong Pharmaceutical Co. LTD. phase 3 Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mosapride class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gasmotin — Competitive Intelligence Brief. https://druglandscape.com/ci/mosapride. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: